Key clinical point: Pulmonary sarcomatoid carcinomas are extremely sensitive to anti–programmed death-ligand 1 therapy.
Major finding: The objective response rate was 80% and clinical benefit rate was100%.
Study details: A retrospective case series of five patients plus historical patients for comparison purposes.
Disclosures: The study was internally funded. Dr. Sukrithan reported having no disclosures.
Sukrithan V et al. ASCO-SITC, Abstract 115.